G1 THERAPEUTICS (NASDAQ:GTHX) posted its earnings results on Wednesday. The company reported ($1.09) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.61) by $0.48, MarketWatch Earnings reports.

G1 THERAPEUTICS (NASDAQ:GTHX) traded up 0.48% during midday trading on Thursday, hitting $12.59. 12,765 shares of the stock traded hands. The firm’s 50-day moving average is $15.54 and its 200-day moving average is $16.31. The company’s market cap is $18.63 million. G1 THERAPEUTICS has a 52-week low of $12.04 and a 52-week high of $20.60.

In related news, insider Ra Capital Healthcare Fund Lp purchased 400,000 shares of the business’s stock in a transaction dated Monday, May 22nd. The shares were purchased at an average cost of $15.00 per share, for a total transaction of $6,000,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Clay Thorp purchased 133,333 shares of the business’s stock in a transaction dated Monday, May 22nd. The stock was bought at an average price of $15.00 per share, for a total transaction of $1,999,995.00. The disclosure for this purchase can be found here. Over the last 90 days, insiders bought 833,333 shares of company stock worth $12,499,995.

Several equities research analysts have recently commented on the stock. Needham & Company LLC assumed coverage on shares of G1 THERAPEUTICS in a research report on Monday, June 12th. They issued a “buy” rating and a $34.00 target price for the company. Cowen and Company assumed coverage on shares of G1 THERAPEUTICS in a research report on Monday, June 12th. They issued an “outperform” rating and a $31.00 target price for the company. Wedbush assumed coverage on shares of G1 THERAPEUTICS in a research report on Monday, June 12th. They issued an “outperform” rating and a $31.00 target price for the company. Finally, J P Morgan Chase & Co assumed coverage on shares of G1 THERAPEUTICS in a research report on Monday, June 12th. They issued an “overweight” rating and a $23.00 target price for the company.

TRADEMARK VIOLATION NOTICE: This news story was originally published by Daily Political and is the property of of Daily Political. If you are reading this news story on another domain, it was stolen and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.dailypolitical.com/2017/08/10/g1-therapeutics-nasdaqgthx-releases-quarterly-earnings-results-misses-expectations-by-0-48-eps.html.

G1 THERAPEUTICS Company Profile

G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.

Receive News & Ratings for G1 THERAPEUTICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 THERAPEUTICS and related companies with MarketBeat.com's FREE daily email newsletter.